EU/3/11/912: Orphan designation for the prevention of graft loss in pancreatic islet transplantation
Table of contents
On 27 September 2011, orphan designation (EU/3/11/912 was granted by the European Commission to Dompé S.p.A., Itlay, for reparixin for the prevention of graft rejection in pancreatic islet transplantation.
The sponsorship was transferred to Dompé farmaceutici s.p.a., Italy, in March 2015.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Prevention of graft loss in pancreatic islet transplantation
|Orphan designation status||
|EU designation number||
|Date of designation||
Dompé farmaceutici s.p.a.
Via Santa Lucia 6
Tel. +39 02 58 38 35 59
Fax +39 02 36 02 69 27
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: